临床用肿瘤细胞凋亡核医学显像剂研究进展

Progress of nuclear medicine imaging agents for the clinical apoptosis imaging of tumors

凋亡在肿瘤的发生、发展和治疗中发挥重要的作用，因此无创、动态监测凋亡已成为目前抗肿瘤治疗的研究热点。目前已有靶向外翻细胞膜磷脂显像剂^99Tc^m-4，5-2（硫代乙酰胺）戊酰-膜联蛋白V和^99Tc^m-联肼尼克酰胺-膜联蛋白V、靶向半胱天冬酶（caspases）显像剂^18F-ICMT-11和^18F-CP18、靶向凋亡细胞膜印迹显像剂^18F-ML-10进入临床试验阶段，虽然它们存在局限性，但当与传统的成像手段比较时，它们在肿瘤的诊断、治疗监测上具备一定的优越性。因此，肿瘤凋亡显像剂具有广泛的应用前景。笔者就目前核医学肿瘤细胞凋亡显像剂在肿瘤诊疗中的研究进展进行综述。

Apoptosis plays a key role in the development and treatment of tumors;thus,the invasive dynamic monitoring of apoptosis is of considerable interest in the management of cancer.At present,^99Tc^m-BTAP-Annexin V,^99Tc^m-HYNIC-Annexin V,^18F-ICMT-11,^18F-CP18,and ^18F-ML-10 have achieved clinical application.Despite their limitations,these agents are superior to conventional imaging technique in the diagnosis and therapeutic monitoring of cancer and can exhibit potential in clinical applications.This review provides an overview of the recent development in apoptosis imaging by using radionuclide-labeled tracers in the management of cancer